Table 3.

Randomized controlled trials of CCTA in patients with stable chest pain

Trial	PROMISE63	SCOT-HEART65	CRESCENT I67	CAPP68	Min et al.69
Sample size	10 003	4146	350	500	180
Comparator	Functional testing	Standard care	Functional testing	EST	Myocardial perfusion imaging
Primary endpoint	Death, nonfatal MI, hospitalization for unstable angina, and major procedural complications	Death from coronary heart disease or nonfatal MI	Absence of chest pain complaints after 1 year	Difference in the change in scores within the Seattle Angina Questionnaires from baseline to 3 months	Angina-specific health status
Duration of follow-up	2.1 years	4.8 years	1.0 years	1.0 years	55 days
Main findings	No difference in clinical outcome	Reduced rate of fatal and non-fatal MI in the CCTA arm	Fewer patients randomized to cardiac CT reported anginal complaints	Less symptoms at 3- and 12-month follow-up in the CCTA arm	No difference in symptoms
Hazard ratio (95% confidence interval) of MACE	1.04 (0.83–1.29)	0.59 (0.41–0.84)	0.32 (0.13–0.81)	N/A	N/A
Rate of ICA, CCTA vs. comparator	12% vs. 8%	23% vs. 24%	12% vs. 11%	27% vs. 21%	13% vs. 8%
Rate of coronary revascularization, CCTA vs. comparator	6% vs. 3%	13% vs. 12%	9% vs. 7%	15% vs. 7%	8% vs. 1%

CAPP, Cardiac CT for the Assessment of Pain and Plaque; CCTA, coronary computed tomography angiography; CRESCENT, Cardiac CT Versus Exercise Testing in Suspected Coronary Artery Disease; CT, computed tomography; EST, exercise stress electrocardiography test; ICA, invasive coronary angiography; MACE, major adverse cardiovascular events; MI, myocardial infarction; N/A, not available; PROMISE, Prospective Multicenter Imaging Study for Evaluation of Chest Pain; SCOT-HEART, Scottish Computed Tomography of the Heart Trial.